This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Labs: Balancing Growth and Profits

NEW YORK ( TheStreet) -- It's now been two full quarters since healthcare conglomerate Abbott Laboratories (ABT - Get Report) effectively separated itself from its drug business -- spinning off that segment into a new entity called AbbVie (ABBV - Get Report).

The spin-off, which was originally announced in late 2011, was a long-anticipated move, for which Abbott investors cheered. It came with plenty of expectations that the remaining portion of Abbott, which consists of the devices business, would post stronger growth results. But since the separation took effect in January of this year, questions have been raised as to which of the two companies presents the better value.

Shares of AbbVie, which have soared more than 30% on the year, have been one of the best performers within the sector. Abbott, meanwhile, has posted gains of 16%. It's not a terrible performance, but the stock has lagged behind Johnson & Johnson (JNJ) and Medtronic (MDT). Although second-quarter earnings results were better than expected, I didn't see enough to buy shares of Abbott today with my own money.
[Read: <a target="blank" data-add-tracking="true" href=""><em>Here's Why Warren Buffett Is Steering Clear of Regulators</em></a>]

As with the April quarter, revenue growth, which registered at just 2% year over year, was another struggle. Even when adjusting for currency exchange rates, which pushes Abbott's growth rate to 4%, the company still missed estimates. By contrast, it pales in comparison to Johnson & Johnson, which recently posted year-over-year growth of 10%.

As with Johnson & Johnson, which has come to rely heavily on its drugs business, it is Abbott's nutrition business, which now accounts for 31% of the company's revenue, that continues to do all of the heavily lifting. Nutrition was up 8% year-over year. It's starting to appear as if Abbott's international expansion plans are paying dividends.

Management said the strong performance was due to geographic development programs that it projected would have spurred these type of results. In that regard, investors should be encouraged that revenue in both pediatric and adult products are growing better-than-expected at a high-single-digit pace.

To what degree this performance can continue remains to be seen. But for now, I'm not willing to bet against management's plan to achieve 20% operating margin in nutrition over the next two years. Unfortunately, though, this is the extent of the positives that I could draw from the quarter. Outside of the 8% increase in the diagnostics business, I was disappointed by Abbott's performance in its other businesses.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $45.41 -0.09%
ABBV $60.29 -1.37%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs